Jacobs Levy Equity Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.27M Buy
+18,878
New +$2.18M 0.01% 563
2025
Q4
Sell
-3,346
Closed -$281K 1013
2025
Q3
$281K Sell
3,346
-48,795
-94% -$4.02M ﹤0.01% 887
2025
Q2
$4.13M Sell
52,141
-1,290,474
-96% -$103M 0.02% 484
2025
Q1
$121M Sell
1,342,615
-34,822
-3% -$3.25M 0.48% 47
2024
Q4
$137M Sell
1,377,437
-549,238
-29% -$56.6M 0.48% 51
2024
Q3
$219M Buy
1,926,675
+647,882
+51% +$77M 0.84% 22
2024
Q2
$158M Buy
1,278,793
+176,527
+16% +$22.7M 0.65% 30
2024
Q1
$145M Buy
1,102,266
+973,139
+754% +$120M 0.65% 31
2023
Q4
$14.1M Buy
129,127
+11,722
+10% +$1.22M 0.07% 258
2023
Q3
$12.1M Buy
+117,405
New +$12.7M 0.07% 235
2023
Q2
Sell
-2,321
Closed -$247K 1041
2023
Q1
$247K Sell
2,321
-9,237
-80% -$997K ﹤0.01% 886
2022
Q4
$1.28M Sell
11,558
-4,573
-28% -$467K 0.01% 639
2022
Q3
$1.39M Sell
16,131
-195,458
-92% -$17.4M 0.01% 637
2022
Q2
$19.3M Buy
211,589
+75,992
+56% +$6.74M 0.15% 171
2022
Q1
$11.1M Buy
+135,597
New +$10.7M 0.07% 276
2021
Q4
Sell
-7,470
Closed -$561K 1039
2021
Q3
$561K Buy
7,470
+1,005
+16% +$76.4K ﹤0.01% 848
2021
Q2
$503K Sell
6,465
-396,671
-98% -$29.5M ﹤0.01% 859
2021
Q1
$29.7M Buy
403,136
+243,097
+152% +$17.9M 0.23% 117
2020
Q4
$12.5M Buy
160,039
+21,142
+15% +$1.62M 0.11% 216
2020
Q3
$11M Sell
138,897
-426,431
-75% -$33.4M 0.11% 198
2020
Q2
$41.7M Sell
565,328
-182,357
-24% -$13.7M 0.45% 49
2020
Q1
$54.9M Buy
747,685
+497,385
+199% +$39.1M 0.71% 23
2019
Q4
$21.7M Buy
250,300
+35,523
+17% +$2.92M 0.21% 121
2019
Q3
$17.3M Buy
214,777
+146,594
+215% +$11.7M 0.21% 130
2019
Q2
$5.46M Buy
68,183
+58,227
+585% +$4.46M 0.08% 325
2019
Q1
$790K Hold
9,956
0.01% 708
2018
Q4
$726K Sell
9,956
-107,694
-92% -$7.6M 0.01% 668
2018
Q3
$7.96M Sell
117,650
-77,866
-40% -$4.96M 0.11% 212
2018
Q2
$11.3M Sell
195,516
-314,672
-62% -$17.8M 0.18% 162
2018
Q1
$26.5M Sell
510,188
-251,657
-33% -$13.6M 0.44% 58
2017
Q4
$40.9M Buy
761,845
+545,788
+253% +$30.3M 0.72% 10
2017
Q3
$13.2M Buy
216,057
+152,171
+238% +$9.23M 0.26% 131
2017
Q2
$3.91M Buy
63,886
+18,424
+41% +$1.12M 0.08% 279
2017
Q1
$2.76M Buy
45,462
+39,614
+677% +$2.4M 0.06% 354
2016
Q4
$328K Sell
5,848
-218,403
-97% -$12.8M 0.01% 754
2016
Q3
$13.4M Buy
+224,251
New +$13.1M 0.24% 130
2016
Q1
Sell
-1,007,946
Closed -$50.8M 1157
2015
Q4
$50.8M Sell
1,007,946
-31,482
-3% -$1.59M 1.01% 13
2015
Q3
$49M Buy
1,039,428
+45,871
+5% +$2.44M 1% 9
2015
Q2
$54M Sell
993,557
-157,482
-14% -$8.83M 1.03% 9
2015
Q1
$63.1M Buy
1,151,039
+16,579
+1% +$939K 1.07% 9
2014
Q4
$61.5M Buy
1,134,460
+98,868
+10% +$5.51M 1.05% 10
2014
Q3
$58.6M Buy
1,035,592
+178,842
+21% +$10M 0.98% 10
2014
Q2
$47.3M Buy
+856,750
New +$46.7M 0.78% 19
2014
Q1
Sell
-319,189
Closed -$15.2M 965
2013
Q4
$15.2M Buy
319,189
+232,834
+270% +$10.6M 0.23% 137
2013
Q3
$3.92M Buy
+86,355
New +$3.94M 0.07% 314

Other funds holding MRK

Jacobs Levy Equity Management's MRK Position: Q1 2026 in Review

Jacobs Levy Equity Management opened a new position in Merck (MRK) in Q1 2026: 18,878 shares worth $2.27M. The stake represents 0.01% of the portfolio and ranks #563 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in MRK as recently as Q3 2025.

Jacobs Levy Equity Management first reported a position in MRK in Q3 2013 and has held it in 45 quarters since. The position peaked at $219M in Q3 2024. 3,777 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Jacobs Levy Equity Management held 18,878 shares of Merck worth $2.27M as of Q1 2026.
  • Merck was a new Jacobs Levy Equity Management position in Q1 2026.
  • Merck made up 0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #563 holding.
  • Jacobs Levy Equity Management first reported a position in Merck in Q3 2013 and has held it in 45 quarters since.
  • Jacobs Levy Equity Management's Merck position peaked at $219M in Q3 2024.
  • 3,777 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.